AXSM Stock Summary and Trading Ideas (Axsome Therapeutics | NASDAQ:AXSM)

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Axsome Therapeutics trades on the NASDAQ stock market under the symbol AXSM.

As of December 16, 2025, AXSM stock price climbed to $146.78 with 135,315 million shares trading.

AXSM has a beta of 1.05, meaning it tends to be more sensitive to market movements. AXSM has a correlation of 0.17 to the broad based SPY ETF.

AXSM has a market cap of $7.16 billion. This is considered a Mid Cap stock.

Last quarter Axsome Therapeutics reported $171 million in Revenue and -$.68 earnings per share. This beat revenue expectation by $8 million and exceeded earnings estimates by $.19.

In the last 3 years, AXSM traded as high as $152.94 and as low as $53.71.

The top ETF exchange traded funds that AXSM belongs to (by Net Assets): VTI, IWM, VB, VBK, VXF.

AXSM has outperformed the market in the last year with a return of +62.9%, while the SPY ETF gained +13.0%. In the last 3 month period, AXSM beat the market returning +25.7%, while SPY returned +2.5%. However, in the most recent 2 weeks AXSM has underperformed the stock market by returning -1.5%, while SPY returned -0.7%.

AXSM support price is $142.70 and resistance is $149.78 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AXSM shares will trade within this expected range on the day.